Objective A pressing tobacco policy concern is how to help smokers who have little interest in quitting cigarettes, a group that often suffers severe health consequences. By switching from cigarettes to e-cigarettes, they could obtain nicotine, potentially with less harm. We examined if policy-relevant attributes of cigarettes/e-cigarettes might encourage these smokers to switch to e-cigarettes.
Methods An online survey and discrete choice experiment on a nationally-representative sample of adult smokers in the US who reported low interest in quitting (n=2000). We modelled preference heterogeneity using a latent class, latent variable model. We simulated policies that could encourage switching to e-cigarettes.
Results Participants formed two latent classes: (1) those with very strong preferences for their own cigarettes; and (2) those whose choices were more responsive to policies. The latter group’s choices were only somewhat responsive to menthol cigarette bans and taxes; the former group’s choices were unresponsive.
Conclusions The policies studied seem unlikely to encourage harm reduction for individuals with little interest in quitting smoking.
- electronic nicotine delivery devices
Data availability statement
No data are available.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors Guarantor: JB; Conception or design of the work: JB, JLS, LMF, SO, SK-S. Acquisition of the data: JB, JLS. Analysis of the data: JB, JLS. Interpretation of data for the work: JB, JLS, LMF, SO, SK-S. Drafting the work: JB, JLS, LMF, SO, SK-S. Final approval of the version to be published: JB, JLS, LMF, SO, SK-S.
Funding Research reported in this publication was supported by grant numbers U54DA036151 from the NIDA and FDA Center for Tobacco Products (CTP) and K12 DA000167 from NIDA.
Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Food and Drug Administration. It was also supported by the NIHR Oxford Biomedical Research Centre.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.